



# Colombian Journal of Anesthesiology

Revista Colombiana de Anestesiología

www.revcolanest.com.co

OPEN

Wolters Kluwer

## Dipyrone-related granulocytopenia. Case report

### Granulocitopenia por dipirona: reporte de caso

Jorge Enrique Machado-Alba<sup>a,b</sup>, Leidy Viviana Sánchez-Morales<sup>a,b</sup>,  
Luisa Fernanda Rodríguez-Ramírez<sup>a,b</sup>

<sup>a</sup> Grupo de Investigación en Farmacoepidemiología y Farmacovigilancia, Universidad Tecnológica de Pereira

<sup>b</sup> Audifarma S.A. Pereira, Colombia.

**Keywords:** Dipyrone, Agranulocytosis, Pharmacovigilance, Adverse effects, Case Report

**Palabras clave:** Dipirona, Agranulocitosis, Farmacovigilancia, Efectos Adversos, Reporte de caso

#### Abstract

**Introduction:** Dipyrone has been positioned in several countries as one of the first over-the-counter options for pain management. Its possible adverse effects are known worldwide; among them, agranulocytosis is the most lethal, with a mortality of approximately 10% and an associated risk of 1 per 1,000,000 patients.

**Clinical findings, interventions, and outcomes:** A case of a patient who, after 23 days of using dipyrone for pain management, developed a progressive drop in leukocyte count. Other potential causes of the event were ruled out. After dipyrone discontinuation, leukocyte counts returned to their normal values.

**Conclusion:** The probable diagnosis of granulocytopenia as a dipyrone-related adverse drug reaction was established. Although rare, dipyrone-related granulocytopenia, may occur in patients who use this medication for long periods.

#### Resumen

**Introducción:** La dipirona se ha posicionado en varios países como una de las primeras opciones de venta libre al público para el manejo del dolor. Sus posibles efectos adversos son conocidos a nivel mundial; entre ellos, la agranulocitosis es la más letal con una mortalidad aproximada del 10% y un riesgo asociado de 1 por cada 1.000.000 pacientes.

**Hallazgos clínicos, intervención y resultados:** Se presenta un caso de una paciente que luego de recibir 23 días seguidos de dipirona para el manejo del dolor presentó disminución progresiva de los leucocitos documentados en el hemograma. Se descartaron otras posibles causas de dicho evento. Luego de suspender la administración de la dipirona los leucocitos volvieron a sus valores normales.

**Conclusión:** Se estableció la sospecha de diagnóstico probable de granulocitopenia como reacción adversa medicamentosa por dipirona. La granulocitopenia por dipirona aunque poco frecuente, se puede presentar en pacientes que la reciben por largos periodos de tiempo.

#### Introduction

Dipyrone (metamizol) is a drug with analgesic effects used for the treatment of acute post-operative pain, oncologic pain, cramp-like pain, and migraine.<sup>1-3</sup> It was widely used before the 1970s, until an association was started to be found between its use and serious adverse reactions such as agranulocytosis,<sup>4,5</sup> defined as a drop in granulocyte count to less than  $0.5 \times 10^9/L$ ; although infrequent, the associated mortality was 10%, due to the predisposition to develop pneumonia, sepsis, toxic epidermal necrolysis,

How to cite this article: Machado-Alba JE, Sánchez-Morales LV, Rodríguez-Ramírez LF. Dipyrone-related granulocytopenia. Case report. Colombian Journal of Anesthesiology. 2018;46:327-330.

Read the Spanish version of this article at: <http://links.lww.com/RCA/A54>.

Copyright © 2018 Sociedad Colombiana de Anestesiología y Reanimación (S.C.A.R.E.). Published by Wolters Kluwer. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Correspondence: Calle 105 No. 14-140, Pereira, Colombia. E-mail: machado@utp.edu.co

Colombian Journal of Anesthesiology (2018) 46:4

<http://dx.doi.org/10.1097/CJ9.0000000000000053>

and necrotizing fasciitis,<sup>6-9</sup> prompting the Federal Food and Drug Administration (FDA) to ban it in the United States in 1977.<sup>10</sup> Since then, more than 30 countries to date have banned its general use.

Several factors that could contribute to the onset of agranulocytosis, have been proposed, but no direct relationship has been established for any of them so far. The most important include extended use (>14 days), female gender, age (over 60 years), concomitant use of methotrexate, and immune and metabolic susceptibility.<sup>11</sup> The following is a case description that illustrates this effect.

### Patient information

A 59-year-old woman with a history of arterial hypertension, unspecified depressive disorder and a surgical history of cystocele repair in 2010. The pharmacological history included hydrochlorothiazide, losartan, verapamil, acetyl salicylic acid, and fluoxetine.

### Clinical findings

The patient was taken to the emergency service on October 17, 2016 after a traffic accident as a passenger on a motorcycle. She presented with evidence of exposed tibial fracture, bilateral periorbital ecchymosis suggesting skull base fracture, hypotension, and amnesia about the episode. Medical management was initiated with dipyrrone 2g intravenously (iv) every 6 hours, cefazolin 1g iv every 6 hours, and gentamicin 160mg iv every 24 hours.

On the same day, the patient was assessed by the general surgeon and taken to closed thoracostomy due to left pneumothorax. Orthopaedic surgery for open reduction of the tibial fracture was performed during the same

surgical stage. Dipyrrone 1g iv was continued every 6 hours during the postoperative period, together with tramadol 100mg every 8 hours only in case of intense pain, ranitidine 50mg iv every 12 hours, enoxaparin 40mg SQ daily, and the same antibiotic management. The only notorious finding in the initial complete blood count (CBC) was severe anemia (hemoglobin 6.6mg/dL). This result prompted transfusion of 2 units of red blood cells.

On October 19, 2016 the dipyrrone dose was increased to 2g iv every 6 hours, while the rest of the medications were continued with no change. On October 21, 2016 left tibia and fibula plating was performed. The follow-up CBC showed slight improvement of the anaemia (hemoglobin 7 mg/dL). Thoracostomy was removed on October 21, 2016 the clinical course continued uneventfully and management continued unchanged. Serial follow-up blood tests remained within normal limits. On October 26, 2016, the patient was assessed by the maxillofacial surgeon who performed orbital floor reconstruction; 1 unit of packed red blood cells was transfused during the procedure. Thoracentesis was scheduled because of a reported left pleural effusion found on computed axial tomography of the chest, quantified at 471 mL on chest ultrasound. However, drainage was postponed due to suspected cellulitis in the left hemithorax, which in the end was found to be only skin irritation caused by the adhesive tape. The orthopaedic surgeon and the maxillofacial surgeon discharged the patient. The clinical course continued while waiting for the thoracentesis procedure. A new chest ultrasound scan performed on November 7, 2016 showed persistent left pleural effusion, which prompted new follow-up tests before the procedure, including CBC done on November 8, 2017 which showed leukopenia, neutropenia, and lymphopenia (Table 1), and creatinine and blood urea nitrogen within normal limits.

**Table 1. Complete blood count testing of a female patient admitted with multiple fractures during the time of dipyrrone use and after its discontinuation**

Parameter/Dates	17/10/16	18/10/16	20/10/16	22/10/16	24/10/16	27/10/16	03/11/16	08/11/16	09/11/16	11/11/16
Leukocytes	23,470	9260	8070	9620	8100	11,210	5710	2900	1920	5150
Neutrophils	17,500	7200	5350	6440	4910	7490	2650	1190	850	1950
Lymphocytes	3920	1180	1780	1720	1920	2230	1510	830	560	1.920
Hemoglobin	9.5	6.6	8.6	7	6.7	8.4	9.9	10.4	10.8	12.4
Hematocrit	29.5	20	25.9	21	21.7	27.5	33	33.6	34.2	39.2
MCV	93	89.7	90.2	93.1	95.2	95.2	97.9	95.5	92.4	92.7
RDW	12.6	13	13.9	14.7	15.4	15.8	16.6	15.6	15.2	14.9
Platelets	274,000	188,000	188,000	240,000	281,000	418,000	671,000	413,000	343,000	321,000

MCV=medium corpuscular volume, RDW=red cell distribution width.  
Source: Authors.

## Therapeutic intervention

Thoracentesis performed on November 9, 2016 retrieved 180 mL of serous material which was sent for analysis, and was found to be a serous exudate with no signs of infection. However, due to the CBC findings, the internal medicine physician decided to discontinue dipyrone after 23 days of administration. The follow-up CBC showed worsening of white blood cell counts.

## Follow-up and results

Stringent follow-up continues with CBC results showing improvements in the parameters mentioned previously (see Table 1).

## Diagnosis evaluation

After applying the algorithm by Naranjo et al, the diagnosis is probable leukopenia related to the use of dipyrone. The patient was discharged and asked to come back in 1 month with a follow-up CBC. The radiological course of the pleural effusion was satisfactory and the general surgeon decided to discharge the patient and order outpatient follow-up.

## Time line

Table 1 shows the results of all the complete blood count tests taken during the time the patient remained in the hospital.

## Discussion

Dipyrone is a pyrazolone derivative with analgesic, antipyretic, and antispasmodic effects, but with little anti-inflammatory effect.<sup>1,7</sup> It is used in the management of postoperative pain, cramp-like pain, cancer pain, and migraine; although its use is very controversial in many countries because of the risk of agranulocytosis, it is still sold over the counter in other countries.<sup>12</sup>

Its antipyretic effect is believed to be due to a reduction in blood levels of prostaglandin E<sub>2</sub> followed by an antipyretic effect on the EP3 located on anterior hypothalamic thermoregulatory neurons.

Associated adverse effects include nausea, vomiting,<sup>1</sup> hypotension, cardiogenic shock,<sup>13,14</sup> exanthemata, urticaria,<sup>5</sup> interstitial nephritis, acute renal failure,<sup>15</sup> anaphylaxis,<sup>16</sup> and Stevens-Johnson syndrome,<sup>17</sup> pancytopenia, and agranulocytosis,<sup>1,6,18</sup> these latter 2 being the conditions that have limited its widespread use. Regarding agranulocytosis, several explanations have been proposed: one of the theories suggests a toxic effect on peripheral blood caused by aminopyrine where drug-dependent anti-neutrophil antibodies are formed which then induce the formation of immune complexes with

the drug, leading to neutrophil cell lysis.<sup>19</sup> However, lysis of these leukocytes may also occur in the bone marrow given that one of the metabolites of dipyrone is capable of interacting with lysine chains in the cell, and triggering an immune response. Another theory proposes that neutrophils produce reactive oxygen species capable of oxidizing some drugs into reactive products which act as haptens, inducing antibody formation.<sup>7,20</sup> Another immune mechanism suggests a reduced in vitro growth of myeloid progenitor cells, multipotent primitive progenitor cells and erythroid progenitor caused by dipyrone in an in vitro culture of bone marrow and CD34+ cells.<sup>21</sup>

On the other hand, several factors have been proposed as contributors to the onset of agranulocytosis, including exposure to high doses, prolonged treatment (>14 days), female gender, age over 65 years, drug interactions, and genetic predisposition.<sup>1,11</sup> However, no direct relationship has been established with dipyrone-induced agranulocytosis for any of them.<sup>11,22</sup>

We present the case of a 59-year-old female in a multiple-trauma context, managed with dipyrone for 23 days, and who developed granulocytopenia from no other apparent cause. No temporal association could be found between the other medications she received and this same type of adverse event. When the drug was discontinued, the follow-up complete blood count showed evidence of increased leukocytes. The patient did not have an underlying infectious process and was discharged with no additional complication. In accordance with the protocols and recommendations required in these types of events, the algorithm by Naranjo et al<sup>23</sup> was applied in an attempt to establish a causality association. The result was a score of 7, consistent with a probable adverse drug reaction.

Although this reaction is infrequent in our setting, physicians and staff caring for patients with pain for prolonged periods should bear in mind the risk of using dipyrone for more than 14 days, as well as its associations with a drop in white blood cell counts and, consequently, immunosuppression and increased probability of infection.

## Patient perspective

The patient only expressed her gratitude for the care received and because she was able to walk again.

## Ethical disclosures

**Protection of human and animal subjects.** The case report was prepared with the informed consent of the family, in accordance with Resolution No. 8430 of 1993 of the Colombian Ministry of Health, guaranteeing patient information confidentiality pursuant to the principles of the Declaration of Helsinki.

**Confidentiality of data.** The authors declare that they have followed the protocols of their work center on the publication of patient data.

**Right to privacy and informed consent.** The authors have obtained the informed consent of the and 2 witnesses. This document work in the power of the correspondence author.

### Funding comment

No funding was received for this work.

### Conflicts of interest

The authors report no conflicts of interest.

### References

- Buitrago-González TP, Calderón-Ospina CA, Vallejos-Narváez Á. Dipyrrone: Benefits underestimated or oversized risks? Review of the literature. *Rev Colomb Cienc Quím Farm* 2014;43:173–195.
- Derry S, Faura C, Edwards J, et al. Single dose dipyrrone for acute postoperative pain. *Cochrane Database Syst Rev* 2010;9:CD003227.
- Koster HT, Avis HJ, Stevens MF, et al. Metamizole in postoperative pain management. *Ned Tijdschr Geneesk* 2012;156:A4323.
- Montoya GA, Vaca C, Parra MF. Adverse events associated with tramadol and dipirone administration in a level III hospital. *Biomédica* 2009;29:369–381.
- Salgado P, Suarez-de-la-Rica A, Maseda E, et al. Severe Mucor necrotizing fasciitis associated to dipyrrone-induced agranulocytosis. *Rev Esp Quimioter* 2015;28:58–60.
- Basak GW, Drozd-Sokołowska J, Wiktor-Jedrzejczak W. Update on the incidence of metamizole sodium-induced blood dyscrasias in Poland. *J Int Med Res* 2010;38:1374–1380.
- Arbeláez-Quintero I, Jiménez-Cardozo N. Agranulocytosis risk during use of Dipyrrone: a systematic literature review. *Salutem Scientia Spiritus* 2015;1:19–24.
- Hamerschlak N, Cavalcanti AB. Neutropenia, agranulocytosis and dipyrrone. *Sao Paulo Med J* 2005;123:247–249.
- Iskra MP, Membrilla E, Isbert F, et al. Severe sepsis due to cervical abscess after agranulocytosis associated with metamizole. *Cir Esp* 2015;93:e83–e85.
- Dorr VJ, Cook J. Agranulocytosis and near fatal sepsis due to 'Mexican aspirin' (dipyrrone). *South Med J* 1996;89:612–614.
- Blaser LS, Tramonti A, Egger P, et al. Hematological safety of metamizole: retrospective analysis of WHO and Swiss spontaneous safety reports. *Eur J Clin Pharmacol* 2015;71:209–217.
- Aronson JK. *Metamizole (dipyrrone) A2 - Meyler's Side Effects of Drugs*. 16th ed. Oxford: Elsevier; 2016; 859–862.
- Kose N, Akin PP. PP-216 a case of inferior acute myocardial infarction due to intravenous metamizole use. *Int J Cardiol* 2013;163 (3 suppl 1):S166.
- Garcipérez de Vargas FJ, Mendoza J, Sánchez-Calderón P, et al. Cardiogenic shock secondary to metamizole-induced type II Kounis syndrome. *Rev Esp Cardiol* 2012;65:1138–1139.
- Redondo-Pachon MD, Enriquez R, Sirvent AE, et al. Acute renal failure and severe thrombocytopenia associated with metamizole. *Saudi J Kidney Dis Transpl* 2014;25:121–125.
- Machado-Alba JE, Urbano-Garzón SF, Gallo-Gómez YN, Zuluaga S, Henao Y, Parrado-Fajardo IY. Reacción de anafilaxia grave por dipirone sin antecedente de hipersensibilidad. Informe de caso. *Rev Colomb Anestesiol* 2017;45:8–11.
- Stamer UM, Soehle M, Park T-W, et al. Anaphylactic reaction after intravenous dipyrrone. *Acute Pain* 2007;9:221–227.
- Hedenmalm K, Spigset O. Agranulocytosis and other blood dyscrasias associated with dipyrrone (metamizole). *Eur J Clin Pharmacol* 2002;58:265–274.
- Ip J, Uetrecht JP. In vitro and animal models of drug-induced blood dyscrasias. *Environ Toxicol Pharmacol* 2006;21:135–140.
- Uetrecht JP, Ma HM, MacKnight E, et al. Oxidation of aminopyrine by hypochlorite to a reactive dication: possible implications for aminopyrine-induced agranulocytosis. *Chem Res Toxicol* 1995;8: 226–233.
- Hargis JB, La Russa VF, Redmond J, et al. Agranulocytosis associated with "Mexican aspirin" (dipyrrone): evidence for an autoimmune mechanism affecting multipotential hematopoietic progenitors. *Am J Hematol* 1989;31:213–215.
- Ibáñez L, Vidal X, Ballarín E, et al. Agranulocytosis associated with dipyrrone (metamizol). *Eur J Clin Pharmacol* 2005;60:821–829.
- Busto U, Naranjo CA, Sellers EM. Comparison of two recently published algorithms for assessing the probability of adverse drug reactions. *Br J Clin Pharmacol* 1982;13:223–227.